Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

(Photo courtesy of Adam Seif) Michael Headrick of Indianapolis wanted to start on a new GLP-1 medication for weight loss, so he mentioned Eli Lilly and Co.’s Zepbound to his doctor, who agreed ...